<div id="readability-page-1"><div> By Nicholas G. Miller <pre></pre> Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending. The company posted net income of $2.69 billion, or 47 cents a share, compared with $2.97 billion, or 52 cents a share, the year prior. Adjusted earnings were 75 cents a share. Analysts polled by FactSet expected 72 cents a share. The company said its research and development expenses rose 12% due to higher spending in certain oncology and obesity product candidates. Cost of sales also increased on the unfavorable impact of foreign exchange and the favorable revision of the company's estimate of accrued royalties in the first quarter of 2025. Revenue rose 5% to $14.45 billion. Wall Street expected $13.84 billion. The gains were driven by growth for its Padcev cancer drug, its Eliquis blood thinner, Oncology biosimilars and its Nurtec migraine treatment and were partially offset by declines in COVID-19 product revenues. Demand for Pfizer's Covid-19 pharmaceuticals has fallen precipitously since the peak of the pandemic and the company has been looking for new drugs to make up for the drop-off in sales. As part of its strategy to beef up its pipeline, Pfizer agreed to acquire weight-loss drug startup Metsera last year in a deal that could be worth more than $10 billion. The company reiterated its full-year guidance for revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Analysts see full-year sales of $61.38 billion and adjusted earnings of $2.96 a share. <pre></pre> Write to Nicholas G. Miller at nicholas.miller@wsj.com. <pre></pre> (END) Dow Jones Newswires May 05, 2026 07:31 ET (11:31 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

輝瑞

基因改革 ETF - ARK

標普生物技術 ETF - SPDR

輝瑞報告第一季度收入增長 5%，達到 144.5 億美元，超出華爾街預期。然而，淨收入下降至 26.9 億美元，受到研發費用上漲 12% 的影響。調整後的每股收益為 75 美分，超過分析師預測的 72 美分。公司仍面臨 COVID-19 產品銷售下滑的挑戰，並專注於新藥開發，包括收購 Metsera。輝瑞維持全年收入指引在 595 億美元至 625 億美元之間，調整後每股收益在 2.80 美元至 3 美元之間

Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending

- 輝瑞第一季度收入增長 5% 至 144.5 億美元，低於華爾街預期。  
- 淨收入為 26.9 億美元，下降主要因研究開發支出上升 12%。  
- 公司維持全年收入指引在 595 億至 625 億美元之間。

MorningStar

Invesco Nasdaq Biotechnology ETF

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - Vanguard

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

Direxion Daily Biotech Top 5 Bull 2X ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

標普全球醫療股指數 ETF - iShares

醫療業 ETF - SPDR

美國制藥 ETF - iShares

輝盛研究系統

Metsera

輝瑞第一季度收入增長，但由於研發支出增加，利潤下降